Company: BOLT
Filing Date: 2025-03-24
Form Type: 10-K
Source: 0000950170-25-043873
Chunk: 236

Company: Bolt Biotherapeutics, Inc.
Filing Date: 2025-03-24
Form: 10-K
Item: Item 8
Chunk 236
---
 (2,615
    )

    (4,493
    )

    Gain on sale of fixed assets

    (70
    )

    —

    Asset impairment

    1,469

    —

    Non-cash lease expense

    2,297

    2,952

    Changes in operating assets and liabilities:

    Prepaid expenses and other assets

    2,571

    (454
    )

    Accounts payable and accrued expenses

    (4,883
    )

    (3,413
    )

    Operating lease liabilities, net

    (1,412
    )

    (2,392
    )

    Deferred revenue

    (4,673
    )

    (3,606
    )

    Other long-term liabilities

    (43
    )

    1

    Net cash used in operating activities

    (61,289
    )

    (69,525
    )

    CASH FLOWS FROM INVESTING ACTIVITIES:

    Purchase of property and equipment

    (41
    )

    (206
    )

    Proceeds from sales of property and equipment

    148

    —

    Purchases of marketable securities

    (88,855
    )

    (164,988
    )

    Maturities of marketable securities

    146,324

    236,232

    Net cash provided by investing activities

    57,576

    71,038

    CASH FLOWS FROM FINANCING ACTIVITIES:

    Proceeds from issuance of common stock

    108

    253

    Net cash provided by financing activities

    108

    253

    NET (DECREASE) INCREASE IN CASH

    (3,605
    )

    1,766

    Cash, cash equivalents and restricted cash at beginning of year

    12,575

    10,809

    Cash, cash equivalents and restricted cash at end of period
     
    $
    8,970

    $
    12,575

    Reconciliation of cash, cash equivalents and restricted cash:

    Cash and cash equivalents
     
    $
    7,205

    $
    10,810

    Restricted cash

    1,765

    1,765

    Total cash, cash equivalents and restricted cash
     
    $
    8,970